Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery

Inclusion Criteria:

• Participants who are candidates for routine, uncomplicated cataract surgery

• Participants who, in the Investigator's opinion, have potential postoperative pinholeSnellen visual acuity (VA) of at least 20/200 in the study eye.

• Participants must be willing to wait to undergo cataract surgery on the fellow eyeuntil after the study has been completed.

Exclusion Criteria:

• Participants who are expected to require concurrent ocular therapy (either eye) withnonsteroidal anti-inflammatory drugs (NSAIDs), mast cell stabilizers, antihistamines,or decongestants.

• Participants who are expected to require treatment with any systemic or ocular (eithereye) corticosteroids or glucocorticoids.

• Participants who are expected to require concurrent ocular therapy withimmunosuppressants (eg, Restasis).

• Participants who have known hypersensitivity or contraindication to the study drug(s)or their components.

• Participants participating in any drug or device clinical investigation within 30 daysprior to entry into this study and/or during the period of study participation.